A Study to Describe the Fertility Journey of Risdiplam-Treated Adult Male Individuals with Spinal Muscular Atrophy

The MARLIN Study is an observational study aimed at understanding the fertility experiences of men diagnosed with spinal muscular atrophy (SMA) who are actively attempting to conceive or have conceived in the past and are taking or have taken risdiplam.

Approximately 30 male participants from the U.S. will join this study. Female partners/ surrogates/ gestational carriers also have the option to take part in this study.

About the MARLIN Study

The MARLIN Study will gather information about the fertility experiences of men diagnosed with SMA who are taking or have taken risdiplam.

The study consists of questionnaires only. It does not include any treatments or procedures such as laboratory tests or doctor visits.

Participants will be asked to complete a questionnaire upon enrollment. For some participants, this will be the end of the study. Other participants will be asked to complete a follow-up questionnaire annually for up to 4 years. Each questionnaire will be completed on a smartphone application (i.e., app) and will take approximately 20-45 minutes to complete.

Female partners/ surrogates/ gestational carriers who decide to participate will be asked to complete similar questionnaires. Male participants can take part in this study, whether or not their female partner/ surrogate/ gestational carrier decides to participate in the study.

Why Participate?

Should you qualify and choose to participate, you will be asked to provide information that may help doctors and researchers better understand the overall impact of risdiplam, an FDA-approved medication for SMA. Taking part in this study is your choice. You can leave the study at any time.

Who Can Participate?

To be considered for this study, participants must be:

  • Diagnosed with SMA
  • Male between 18 and 50 years of age
  • Currently taking risdiplam OR previously took risdiplam
  • Actively trying to conceive OR conceived in the past (during or after taking risdiplam)

Female partners/ surrogates/ gestational carriers also have the option to participate in this study.

How to Enroll

If you are interested in participating in the MARLIN Study, please provide your contact information so a member of the study team can follow up with you. You will be compensated for participating in the study.

Provide your contact information

For Healthcare Providers:

If you would like to refer a patient who is eligible and interested in participating in the MARLIN Study, please contact the study team:

Phone number

Call 1-855-662-7546 (1-855-6MARLIN)

Hours of operation

Hours of Operation: Monday-Friday, 8am- 5pm ET

Download Brochure

Brochure